151 related articles for article (PubMed ID: 31678469)
1. Home-based contact immunotherapy with diphenylcyclopropenone improves compliance with the recommended follow-up for patients with alopecia areata: A retrospective cohort study.
Kim BJ; Lee S; Lee CH; Lee WS
J Am Acad Dermatol; 2020 May; 82(5):1223-1225. PubMed ID: 31678469
[No Abstract] [Full Text] [Related]
2. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases.
Choe SJ; Lee S; Pi LQ; Keum DI; Lee CH; Kim BJ; Lee WS
J Am Acad Dermatol; 2018 Mar; 78(3):515-521.e4. PubMed ID: 29108907
[TBL] [Abstract][Full Text] [Related]
3. Treatment of alopecia areata with diphenylcyclopropenone.
van der Steen PH; van Baar HM; Perret CM; Happle R
J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):253-7. PubMed ID: 2007671
[TBL] [Abstract][Full Text] [Related]
4. Urticaria after topical immunotherapy with diphenylcyclopropenone.
Francomano M; Seidenari S
Contact Dermatitis; 2002 Nov; 47(5):310-1. PubMed ID: 12534538
[No Abstract] [Full Text] [Related]
5. Home-based contact immunotherapy with diphenylcyclopropenone for alopecia areata is as effective and safe as clinic-based treatment in patients with stable disease: A retrospective study of 40 patients.
Lee S; Lee WS
J Am Acad Dermatol; 2018 Mar; 78(3):599-601.e1. PubMed ID: 28947296
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
7. Alopecia areata: topical immunotherapy--application and practical problems.
MacDonald N; Wiseman MC; Shapiro J
J Cutan Med Surg; 1999 Nov; 3 Suppl 3():S36-40. PubMed ID: 11776938
[No Abstract] [Full Text] [Related]
8. Topical immunotherapy with diphencyprone in the treatment of extensive and/or long-lasting alopecia areata.
Firooz A; Bouzari N; Mojtahed F; Pazoki-Toroudi H; Nassiri-Kashani M; Davoudi M; Dowlati Y
J Eur Acad Dermatol Venereol; 2005 May; 19(3):393-4. PubMed ID: 15857483
[No Abstract] [Full Text] [Related]
9. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
Lee S; Kim BJ; Lee YB; Lee WS
JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
[TBL] [Abstract][Full Text] [Related]
10. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months.
van der Steen PH; Boezeman JB; Happle R
Dermatology; 1992; 184(3):198-201. PubMed ID: 1392112
[TBL] [Abstract][Full Text] [Related]
11. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy.
von Moos S; Johansen P; Waeckerle-Men Y; Mohanan D; Senti G; Häffner A; Kündig TM
Allergy; 2012 May; 67(5):638-46. PubMed ID: 22380933
[TBL] [Abstract][Full Text] [Related]
12. Topical immunotherapy with contact allergens in alopecia areata: evidence for non-specific systemic suppression of cellular immune reactions.
Bröcker EB; John SM; Steinhausen D; Hamm H
Arch Dermatol Res; 1991; 283(2):133-4. PubMed ID: 2069412
[No Abstract] [Full Text] [Related]
13. Age dependence of diphenylcyclopropenone sensitization in patients with alopecia areata.
Temesvári E; González R; Marschalkó M; Horváth A
Contact Dermatitis; 2004 Jun; 50(6):381-2. PubMed ID: 15274737
[TBL] [Abstract][Full Text] [Related]
14. Topical immunotherapy in the treatment of chronic severe alopecia areata.
Shapiro J
Dermatol Clin; 1993 Jul; 11(3):611-7. PubMed ID: 8365043
[TBL] [Abstract][Full Text] [Related]
15. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F
Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation.
Shapiro J; Tan J; Ho V; Tron V
J Invest Dermatol; 1995 May; 104(5 Suppl):36S. PubMed ID: 7738390
[No Abstract] [Full Text] [Related]
17. Cytokine patterns in alopecia areata before and after topical immunotherapy.
Happle R; Hoffmann R
J Invest Dermatol; 1995 May; 104(5 Suppl):14S-15S. PubMed ID: 7537782
[No Abstract] [Full Text] [Related]
18. Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study.
Lee S; Lee H; Lee CH; Lee WS
Indian J Dermatol Venereol Leprol; 2019; 85(4):431-433. PubMed ID: 31062723
[No Abstract] [Full Text] [Related]
19. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
20. Home-based diphenylcyclopropenone immunotherapy for alopecia areata: A large retrospective study of 94 cases.
Nam KH; Lee GJ; Kim JI; Song KH; Park J
J Dermatol; 2023 Aug; 50(8):1093-1095. PubMed ID: 37334761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
